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ABSTRACT 1 
 2 
Background. Immunotherapy has shown efficacy in small cell lung cancer 3 
(SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently 4 
needed. Our aim was to evaluate serum Th1, Th2 and proinflammatory cytokines 5 
in two cohorts of SCLC patients before and during treatment with chemotherapy 6 
with or without ipilimumab and to correlate them with survival. 7 
Patients and methods. Two cohorts of SCLC patients were studied: patients 8 
treated with chemotherapy (n=47), and patients treated with chemotherapy plus 9 
ipilimumab (n=37). Baseline, on-treatment and after-treatment serum samples 10 
were evaluated for the presence of IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN-11 
gamma, TNFalpha, GM-CSF and Mip-1alpha using a Luminex assay. Differential 12 
changes of cytokines between cohorts were analyzed. Associations between 13 
cytokine levels and their changes with overall survival were evaluated. 14 
Results. Patients treated with ipilimumab showed a global increase of all 15 
cytokines after treatment initiation. A high level of IL-8 at baseline was associated 16 
with worse prognosis regardless of treatment. Baseline increased IL-2 levels 17 
predicted sensitivity to ipilimumab, while high IL-6 and TNFalpha predicted 18 
resistance. An on-treatment increase in IL-4 levels in patients treated with 19 
immune-chemotherapy was associated with a better overall survival. 20 
Conclusions. The addition of ipilimumab to standard chemotherapy in SCLC 21 
modulates the serum levels of cytokines. Baseline levels and their change over 22 
time relate to overall survival. Blood based biomarkers are convenient for patients 23 
 6 
and our results support prospective validation of cytokines as predictive 1 
biomarkers for ipilimumab in SCLC.  2 
 3 
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 7 
INTRODUCTION 1 
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. 2 
Platinum-based chemotherapy has been the standard of care for the last three 3 
decades and unfortunately varying combinatorial systemic approaches have not 4 
improved survival 1,2. The substantial incidence of autoimmune paraneoplastic 5 
immune events 3 and the high tumor mutational burden 4 suggest that immune 6 
modulation is a promising strategy in SCLC 5.  7 
Consistent with these concepts, immune checkpoint inhibitors have shown 8 
some activity in SCLC 6±10. Ipilimumab, a fully human immunoglobulin G1 9 
monoclonal that blocks CTLA-4 11, showed a trend to improved overall survival 10 
(OS) when combined with standard chemotherapy in a phase II trial 6. Although 11 
the confirmatory phase III failed to confirm an improvement in OS 2, 12 
combination of anti-CTLA4 and anti-PD1 agents showed a significant antitumor 13 
activity in SCLC patients in second line of treatment, particularly when 14 
ipilimumab is included in the regime 7. 15 
However, two more recent studies of the combination in the maintenance and 16 
second line settings have failed to demonstrate benefit over standard 17 
approaches 12,13. These failed trials have not used any biomarkers for selection 18 
of patients with higher likelihood of benefit and unfortunately this may preclude 19 
these drugs to get to the clinic. Despite this, there is a subset of patients who 20 
benefit from immunotherapy and have long term outcomes when this strategy is 21 
used 2,9. Predictive biomarkers to select patients who will benefit from 22 
immunotherapy are therefore urgently needed. In SCLC additionally the limited 23 
 8 
tissue available for biomarker studies 14 makes blood-based tests particularly 1 
interesting and relevant. 2 
Cytokines are soluble molecular messengers with a crucial role in immune 3 
response signaling 15. While Th1 cytokines (IL-2, IFNJ and TNFD) elicit cell-4 
mediated responses, Th2 cytokines (IL-4, IL-5, and IL-10) direct the T-cell 5 
response away from a protective Th1 phenotype 16,17. The Th1/Th2 cytokine 6 
balance is disrupted in malignant tumors 18±20 favoring an immunosuppressive 7 
microenvironment. There are preliminary data supporting a prognostic role of 8 
inflammatory cytokines such as IL-6 and IL-8 in NSCLC 21,22. However, the 9 
biological impact of cytokine levels has to date not been evaluated in SCLC. 10 
We analyzed serum Th1, Th2 and inflammatory cytokines in two independent 11 
cohorts of SCLC patients treated with standard chemotherapy with or without 12 
the anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody 13 
ipilimumab. Our goal was to evaluate if baseline levels of cytokines or changes 14 
induced by therapy would predict benefit from the addition of ipilimumab in 15 
SCLC and allow insights into the immunological consequence of the addition of 16 
a checkpoint inhibitor. 17 
  18 
 9 
RESULTS 1 
3DWLHQWV¶FKDUDFWHULVWLFV and outcomes 2 
We included 84 SCLC patients. Cohort 1 consisted of 47 patients treated with 3 
platinum ± etoposide; cohort 2 included 37 patients treated with platinum ± 4 
etoposide in combination with ipilimumab 10mg/kg. Patients¶ characteristics are 5 
summarized in Supplementary table S1. Cohort 1 included more men (74.5% vs 6 
64.9%), patients with performance status (PS)=2 (7% vs 0%) and patients with 7 
limited disease (25% vs 0%). Median progression free survival (PFS) was 6.8 8 
months (m) in cohort 1 and 6.9m in cohort 2; median overall survival (OS) was 9 
13.3m in cohort 1 and 17m in cohort 2. 10 
 11 
Serum Th1, Th2 and pro-inflammatory cytokines are lower in SCLC 12 
patients than in a cohort of healthy individuals 13 
We evaluated pre-treatment serum cytokine levels in SCLC patients (both 14 
cohorts combined) in comparison to healthy volunteers. IL-1E, IL-5, Mip-1D and 15 
TNFD were significantly lower in SCLC patients compared with healthy 16 
volunteers (Figure 1; Supplementary Table S2). The remaining cytokines except 17 
IL-6, were also numerically lower in SCLC but the difference was not statistically 18 
significant. When we restricted the analyses to patients with extensive disease, 19 
serum levels of IL-1E, IL-4, IL-5 and Mip-1D were significantly lower in SCLC 20 
patients when compared with healthy volunteers.  21 
 22 
 10 
Baseline cytokine levels correlate with age, PS and stage 1 
We assessed the correlation between the level of cytokines (both cohorts) and 2 
clinical features. Baseline levels of TNFD were significantly higher in patients 3 
over 60 years old; IL-5 was significantly higher in patients with PS 0 vs PS 1/2 4 
and IL-2 was significantly higher in female patients compared with male 5 
(Supplementary Figure S1). IL-4 and Mip-1D were significantly lower in patients 6 
with extensive disease when compared to those with limited disease 7 
(Supplementary Figure S2). 8 
 9 
Ipilimumab globally increases Th1, Th2 and inflammatory cytokines 10 
We next studied how cytokine levels changed once treatment had been started 11 
in each cohort. Patients treated with chemotherapy alone, showed a decrease 12 
of GM-CSF, IFNJ, Mip-1D, IL-1E, IL-2, IL-6 and IL-8 median concentration from 13 
baseline to tumor response; TNFD, IL-5 and IL-10 showed an increase from 14 
baseline to tumor response; and IL-4 levels showed no significant changes. 15 
Patients treated with immunochemotherapy showed a global increase of all 16 
cytokines assessed (IL-1E, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFNJ, TNFD, Mip-1D 17 
and GM-CSF) (Figure 2A and 2B) (Supplementary Table S3). These differences 18 
between cohorts were statistically significant for all cytokines except for GM-19 
CSF and IL-8. 20 
We calculated the percentages of cytokine variation from the first to the second 21 
time-point using previously log2 transformed data. A heatmap of the changes in 22 
cytokine levels after treatment, compared to baseline is displayed in Figure 2C. 23 
 11 
In patients treated with immunochemotherapy, the dominant effect is an 1 
increase on cytokine levels in contrast to a reduction after chemotherapy alone. 2 
Consistent with this, a principal component analysis (PCA) of fold change of 3 
cytokine levels after treatment reveals that patients cluster according to the 4 
treatment received (chemotherapy alone vs immunotherapy) (Figure 2D).  5 
 6 
Baseline IL-8 levels are an unfavorable prognostic marker in SCLC 7 
regardless of treatment 8 
We inquired whether basal levels of cytokines correlated with survival in SCLC. 9 
In both cohorts, patients with serum IL-8 concentration above cut-off, had a 10 
worse OS. In cohort 1, patients with baseline IL-8 above cut-off had a median 11 
OS of 9.2m vs 16.8m of those with lower levels (p=0.028); in cohort 2, patients 12 
with baseline IL-8 above cut-off had a median OS of 5.3m vs 17m of those with 13 
lower levels (p=0.031) (Figure 3). When restricting the analyses to the 14 
advanced disease population we obtained the same outcome. 15 
 16 
Baseline IL-2 levels predict sensitivity to ipilimumab, while IL-6 and TNFD 17 
predict resistance 18 
We evaluated the potential predictive role of cytokines in patients treated with 19 
ipilimumab. Patients treated with immunochemotherapy with a serum IL-2 20 
concentration above cut-off at baseline, had a median OS of 30.5m while those 21 
with lower levels had a median OS of 8m (p=0.015) (Figure 4A). In contrast, 22 
patients with a serum IL-6 above cut-off had a median OS of 9.5m while those 23 
 12 
with lowers levels was 18.5m (p=0.026) (Figure 4B). Patients with a serum 1 
TNFD concentration above cut-off had a median OS of 7.8m while those with 2 
lower levels was 18.5m (p=0.004) (Figure 4C). These associations were not 3 
observed when patients were treated with chemotherapy alone. When we 4 
restricted the analyses to the advanced disease population, all these results 5 
were sustained. Similar results were find when the median cytokine serum level 6 
was used as a cut-off (Supplementary Table S4). The multivariate analyses 7 
showed that high levels of IL-2 were independently associated with sensitivity to 8 
ipilimumab and high levels of IL-6 and TNFD were independently associated 9 
with resistance to ipilimumab (Supplementary Table S5). 10 
 11 
Changes in IL-4 levels during treatment link to outcome in SCLC 12 
We hypothesized that quantitative changes in cytokine levels during treatment 13 
could be associated with survival. Patients treated with chemotherapy alone 14 
whose IL-4 increased more than 23% from baseline to response, had a 15 
significant worse OS (9.5m vs 16.3m; p=0.001). This finding was maintained 16 
when analyzing only the advanced patients, although it lost statistical 17 
significance (p=0.063). However, those treated with immunochemotherapy 18 
whose IL-4 increased more than 32% had a significant better OS (18.5m vs 19 
8.8m; p=0.042) (Figure 5).  20 
 21 
DISCUSSION 22 
 13 
To the best of our knowledge, this is the first study to assess how ipilimumab 1 
affects serum levels of immunomodulatory cytokines in SCLC. Our access to 2 
two cohorts of patients who were treated with either immunochemotherapy or 3 
chemotherapy alone allowed us to assess the biological effect of the addition of 4 
ipilimumab and to interrogate these data in the light of clinical outcomes. 5 
An intriguing result is the observation of concordantly lower serum levels of 6 
multiple cytokines in SCLC patients compared to healthy controls. In the 7 
literature we only found 3 patients that had been evaluated in this way 23; a 8 
functional study on whole blood stimulated in vitro revealed a lower cytokine 9 
release in cells from SCLC patients, perhaps offering an insight into the 10 
underpinning biology of our observation 24. More data are available on 11 
circulating IL-6 levels: a study of 72 patients with SCLC identified that in both 12 
limited and extensive disease, elevated IL6 levels could be detected, consistent 13 
with our observation 25. 14 
The modulation of cytokine levels after treatment with immunochemotherapy 15 
has not been previously reported in SCLC. We found that addition of ipilimumab 16 
increased concentrations of the evaluated cytokines globally and appeared to 17 
counteract the effect of chemotherapy that typically decreased cytokines. It is 18 
recognized that SCLC cells may be the source of cytokines and therefore 19 
successful treatment could reduce levels as observed for the majority of 20 
cytokines. This might not be the main source, except for IL-6, as the 21 
pretreatment levels in patients are already lower than in healthy controls. 22 
Immune cells are also sources of cytokines and can be affected by 23 
chemotherapy-induced apoptosis, likely contributing to the observed decrease. 24 
Notably, however, patients treated with chemotherapy alone showed 25 
 14 
stabilization or increase in levels of TNFD and Th2 cytokines. These data 1 
suggest that the important compartment of cells contributing to the presence of 2 
these cytokines might not be affected by chemotherapy, for example M2 3 
macrophages in the tumor microenvironment 26,27. In the absence of paired 4 
samples of tumor tissue, we were unable to evaluate this directly. Ipilimumab 5 
has previously been reported to increase secretion of IFN-Ȗ,/-2R, IL-12, and 6 
IL-13 from PBMC in vitro exposure 28, consistent with its proposed release of 7 
activated T-cells from inhibition.  8 
Next, we explored the prognostic and predictive role of cytokine levels at 9 
baseline and during treatment. IL-8 is secreted by malignant cells and tumor 10 
stroma cells; anti-IL-8 antibodies have shown activity in vitro and in vivo 29 and it 11 
is being currently tested in clinical trials (NCT02536469). We found that high 12 
baseline levels of IL-8 were associated with worse OS regardless of treatment 13 
type. This is consistent with previous literature and is probably a surrogate of 14 
tumor burden as it showed a profound decrease with chemotherapy 30. 15 
Interestingly, IL-8 was minimally affected by the addition of ipilimumab. IL-8 has 16 
been  17 
To evaluate the predictive value of cytokine levels after immunochemotherapy, 18 
we analyzed the changes in serum concentrations of each cytokine and 19 
compared the effect on outcome in both cohorts. Although the cohorts have 20 
differences in baseline clinical characteristics, the possibility of comparing the 21 
effects of the combination to chemotherapy alone (standard treatment in SCLC 22 
up to date) provided the opportunity to individualize the effects related to 23 
ipilimumab. Only associations that were significant for the ipilimumab treated 24 
 15 
cohort and were different from those observed in the chemotherapy only arm, 1 
were considered predictive of ipilimumab-linked effects. For instance, serum IL-2 
2 behaved as a predictor of benefit to ipilimumab, and elevated baseline levels 3 
identified patients with a significant longer OS. No such a difference was 4 
observed in patients treated with chemotherapy alone. IL-2 is a cytokine that 5 
promotes the proliferation of T cells, supporting the initiation and maintenance 6 
of immune response 31. Moreover, it stimulates the proliferation of natural killer 7 
cells and enhances their activity 32. As the regulation of T-cell activation through 8 
binding of CTLA4 to B7 may affect IL-2 secretion 33, the release of this blockade 9 
with ipilimumab would increase IL-2 concentration enhancing the immune 10 
response, and could explain the observed better outcome. In contrast, IL-6 and 11 
TNFD behaved as predictors of resistance to ipilimumab: patients with higher 12 
baseline concentrations treated with immunochemotherapy had a shorter OS. 13 
Our data are consistent with observations in other solid cancers: IL-6 has been 14 
associated with tumor progression in lung cancer 34 and to a lack of benefit from 15 
ipilimumab in melanoma 35,36. Moreover, it has been tested as a target in cancer 16 
in vivo 37. TNFĮ has pro-tumorigenic activity in cancer 38 and has been linked to 17 
MAPK inhibitor resistance in melanoma when secreted by macrophages. 18 
Increased serum TNFD might reflect an immunosuppressive tumor 19 
microenvironment explaining the observed associated resistance to ipilimumab. 20 
Although these mechanisms seem plausible, they require further validation.  21 
As serial sampling was available in both cohorts, we evaluated if changes in the 22 
cytokine serum levels could predict for benefit from ipilimumab. Our results 23 
showed that IL-4 levels were not significantly modified in patients treated with 24 
chemotherapy alone. In patients treated with chemotherapy in whom IL-4 25 
 16 
increased we observed a worse overall survival. It is possible that this may be 1 
reflecting an effect on macrophage M2 polarization 39. Interestingly, IL-4 2 
increased in the ipilimumab treated cohort and patients experiencing this 3 
increase had a better outcome. This increase has been observed in mice 4 
treated with ipilimumab but an association with outcome is not observed after 5 
ipilimumab monotherapy 40,41. However, the evidence of the pro or antitumoral 6 
role of IL-4 in the literature is contradictory and its function seems to depend on 7 
IL-4 levels and its association with other immunological modulators 42. Globally, 8 
our results are novel and hypothesis generating, but warrant prospective 9 
validation. 10 
In conclusion, we have observed differential impact of ipilimumab in serum 11 
cytokines in patients with SCLC. Baseline levels and changes on treatment 12 
might serve as convenient predictive biomarkers of benefit from adding 13 
ipilimumab to chemotherapy in a disease where tumor biomarkers studies are 14 
challenging.  15 
  16 
 17 
PATIENTS AND METHODS 1 
Patients and study design 2 
We retrospectively evaluated two independent cohorts of SCLC patients whose 3 
outcomes we have previously reported 43. Patients from cohort 1 were recruited 4 
between November of 2009 and January of 2014 at the Hospital del Mar, 5 
Barcelona and treated with platinum plus etoposide 44,45. Cohort 2 included 6 
patients recruited to a phase II trial of ipilimumab at 10mg/kg, platinum and 7 
etoposide (ICE-trial) 9. We included a control donor population of healthy, age- 8 
and sex-matched individuals (n=30). Sample collection and data analyses were 9 
approved by the local ethics committee of the participating institutions and 10 
informed consent of each study participant was obtained.  11 
 12 
Sample collection 13 
Serum samples were sequentially collected in each cohort: for cohort 1 at 14 
baseline (before starting treatment), at first response evaluation (at 3 months 15 
approximately) and at progression; for cohort 2 at baseline, at 3 and 6 months. 16 
Whole blood samples were collected by standard venipuncture techniques 17 
using serum separator tubes. Samples were allowed to clot for 30 minutes at 18 
room temperature before centrifugation for 10 minutes at 1000 g at 4 C. 19 
Following centrifugation, the supernatant (serum) was immediately removed 20 
and assayed immediately or aliquoted and stored frozen at -80 C until further 21 
use.  22 
 23 
 18 
Cytokine assessment 1 
Serum samples of all patients and healthy donors were evaluated using a 2 
commercially Milliplex map Human High Sensitivity T Cell magnetic bead panel 3 
(Millipore, Billerica, MA, USA) coupled with the Luminex xMAP platform. We 4 
PHDVXUHGDSDQHORI7K,)1Ȗ,L-71)Į7K,/-4, IL-5, IL-10), and 5 
inflammatory cytokines (GM-CSF, IL-1E, IL-6, IL-8) plus MIP-1D in accordance 6 
ZLWKWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV'DWDZDVDQDO\]HGXVLQJILYH-parametric 7 
curve fitting and assay controls included kit standards and Multiplex controls. 8 
Intra-assay variabilities were less than 12%. Duplicate measurements with a 9 
variability higher than 35% were excluded. These experiments were supervised 10 
by technical personal of the Luminex Core Facility at IMIM. 11 
 12 
Cytokine cut-off calculation 13 
To evaluate the association of cytokines levels with survival, we evaluated the 14 
impact of different cut-off methods, including medians (Supplementary Table 15 
S4) and ROC curves (Supplementary Table S6 and Supplementary Figure S3). 16 
Finally, as the endpoint for comparison was overall survival, we used the web-17 
based software Cut-off Finder 46, previously used in the literature 47,48. This 18 
method takes into account this endpoint outcome: for each cytokine we 19 
identified the threshold level at which a log-rank test allowed segregation of 20 
patients into groups with good and poor outcomes (Supplementary Table S7). 21 
Then we calculated the percentage of cytokine median concentration variation 22 
from first to second time-point and considered >5% positive or negative 23 
variations as significant changes (Supplementary Table S8). 
 19 
 1 
Statistical analyses 2 
Statistical analysis was carried out using Stata/MP 14 (StataCorp LLC, Texas, 3 
USA) and Prism 7.0c (GraphPad Software, Inc.). Baseline values of cytokines 4 
were compared among cohorts and healthy volunteers using the non-5 
parametric Mann-Whitney U-test. Overall survival, measured from date of start 6 
of treatment until date of death or last visit, was plotted by the Kaplan-Meier 7 
method and curves were compared with the log-rank test. All tests were 8 
conducted at the two-sided test with 0.05 level of significance. R (v 3.4.3) was 9 
used to log2 transform data, compute cytokine variation and to generate heat 10 
maps (using package gplots) and principal component analysis (PCA). 11 
 12 
 13 
 14 
 15 
16 
 20 
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Figure legends:
 
1 
Figure 1. Baseline Th1, Th2 and pro-inflammatory cytokines are lower in 2 
SCLC patients than in healthy individuals. Dot plots showing the difference 3 
on cytokine titters between healthy volunteers (n = 30) and patients with small 4 
cell lung cancer (n= 84). Top of grey box shows the median value. All cytokines 5 
but IL-6 were decreased in SCLC patients when compared to a healthy 6 
population, although only in the case of IL-1E (p=0.014), IL-5 (p=0.0013), Mip-7 
1D (p=0.0001) and TNFD (p=0.042) these differences were statistically 8 
significant. Error bars show the interquartile range. GM-CSF, Granulocyte-9 
macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; MIP, 10 
Macrophage Inflammatory Protein; TNF, Tumor necrosis factor. *P<0.05, 11 
****P<0.0001 12 
 13 
 14 
  15 
 30 
Figure 2. Evolution of cytokines levels in patients treated with 1 
chemotherapy in combination with ipilimumab. (A) Values correspond to 2 
median cytokine concentration, and p values were obtained taking into account 3 
the difference on the number of patients showing an increase vs decrease of 4 
cytokines levels. B, baseline; R, response; P, progression (B) Bottom of green 5 
bars reflects the variation of change of cytokine concentration from baseline to 6 
second time-point of cohort 1. Top of orange bars reflect the variation of change 7 
of cytokine concentration from baseline to second time-point of cohort 2.  (C) 8 
Hierarchical clustering of changes in cytokine levels in patients treated with 9 
chemotherapy alone (top) and immunochemotherapy (bottom). The heatmap 10 
depicts the fold-change of cytokines from first to second time-point, where blue 11 
represents a decrease, and yellow and increase compared to baseline. The 12 
dominant effect is of reduction of cytokines in patients exposed to 13 
chemotherapy alone, compared to an increase in patients after 14 
immunochemotherapy. (D)  Principal component analysis (PCA) showing the 15 
distribution of patients in three-dimensional space, according to changes in 16 
cytokine levels after treatment. The PCA plot shows the clustering of patient 17 
according to treatment type (chemotherapy alone, green; 18 
immunochemotherapy, orange), visualizing similarities in patterns in changes in 19 
cytokine levels. GM-CSF, Granulocyte-macrophage colony-stimulating factor; 20 
IFN, interferon; IL, interleukin; MIP, Macrophage Inflammatory Protein; TNF, 21 
Tumor necrosis factor. 22 
 23 
  24 
 31 
Figure 3. Baseline IL-8 may be an unfavourable prognostic marker of 1 
response to ipilimumab in SCLC. Patients treated either with chemotherapy 2 
alone or with ipilimumab harbouring a high baseline IL-8 had a worse OS than 3 
those with a low baseline IL-8. mOS: median overall survival. 4 
 5 
 6 
7 
 32 
Figure 4. Baseline concentrations of cytokines may predict benefit from 1 
ipilimumab in SCLC patients. (A) IL-2 appears to predict specific benefit from 2 
ipilimumab. (B) Patients with higher levels of IL-6 present worse OS when 3 
treated with chemoimmunotherapy but not with chemotherapy alone, 4 
suggesting a lack of benefit from ipilimumab in this subgroup. (C) Patients with 5 
higher levels of TNFD had a worse OS. This difference in survival was not 6 
replicated in patients treated with chemotherapy alone. 7 
  8 
 33 
Figure 5. Modulation of IL-4 during treatment in SCLC could predict 1 
outcome. Patients treated with chemotherapy alone whose IL-4 increased 2 
more than 23% from first to second time-point had a shorter OS, while those 3 
treated with immunochemotherapy whose IL-4 increased more than 32% had a 4 
longer OS. 5 
 6 
  7 
 34 
Supplementary figure S1. Baseline levels of TNFD were significantly 1 
increased in patients over 60 years old [9.15 pg/mL vs 6.84 pg/mL (p=0.0067)]; 2 
IL-5 was significantly increased in patients with PS 1 or 2 vs PS 0 [2.83 pg/mL 3 
vs 1.18 pg/mL (p=0.047)]; and IL-2 was significantly increased in female 4 
patients compared with male [2.76 pg/mL vs 1.78 pg/mL (p=0.037)]. 5 
 
6 
Supplementary figure S2. IL-4 and Mip-1D were significantly decreased in 7 
patients with extensive disease when compared to those with limited disease. 8 
 9 
Supplementary figure S3. Among other methods, ROC curves were calculated 10 
to evaluate its impact as a cut off parameter (see Supplementary Table S6). 11 
